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Patients with cystic ﬁbrosis (CF) frequently experience gastrointestinal symptoms including nausea, emesis, malnutrition and indigestion;
diseases such as gastroesophageal reﬂux disease (GERD), distal intestinal obstructive syndrome, and cholelithiasis are commonly implicated. We
have recently diagnosed eosinophilic esophagitis (EoE) in three patients with CF. EoE is a TH-2 driven, allergen-mediated disease which causes
esophageal eosinophilia and presents with symptoms of nausea, feeding intolerance, regurgitation, and dysphagia. EoE is diagnosed when
esophageal biopsies reveal greater than 15 eosinophils per high power ﬁeld in the setting of the appropriate clinical scenario and after exclusion of
other causes of esophageal eosinophilia. Although described with increasing frequently in the gastrointestinal literature, there have been no prior
cases documenting the co-existence of EoE and CF. We speculate that this is related to lack of familiarity with EoE symptoms by CF providers. We
present three patients with CF diagnosed with EoE and review the current literature regarding diagnosis and management, focusing on management
issues in patients with CF.
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Eosinophilic esophagitis (EoE) is a chronic, antigen-driven
allergic disease characterized by eosinophilic infiltration of the
esophagus and symptoms of esophageal dysfunction. First
described in the late 1970s and felt to be relatively rare, EoE
has exhibited an increasing incidence over the past 5–10 years,
due to both increasing recognition of the condition as well as
increasing incidence and prevalence [1]. EoE is defined as a
clinicopathologic condition, and the correct combination of
clinical symptoms and histopathologic findings are required to
confirm the diagnosis [2]. In order to diagnose EoE, current
guidelines require: 1) symptoms of esophageal dysfunction
(dysphagia, food impaction, chest pain, heartburn, and regurgi-
tation, among others); 2) at least 15 eosinophils in at least one
high-power microscopy field (eos/hpf) on esophageal biopsy;
and 3) exclusion of other potential causes of esophageal
eosinophilia [1,2]. While dysphagia and food impaction are the
most common symptoms in adults [2,3], symptoms in children
can be non-specific and include food intolerance, failure-
to-thrive, abdominal pain, nausea, and emesis. Non-specific
gastrointestinal (GI) symptoms such as these are common in
patients with cystic fibrosis (CF), and may be attributable to
CF-related comorbidies such pancreatic insufficiency with
malabsorption, distal intestinal obstruction syndrome (DIOS),
gastroesophageal reflux disease (GERD), infections, medication
side effects, or other conditions. However, in selected cases, EoE
should be considered in the differential diagnosis as it is possible
that EoE and CF can coexist, although to our knowledge this has
not previously been reported in the medical literature. The
purpose of this investigation is to highlight a series of patients
with CF who presented with a range of GI symptoms and were
ultimately diagnosed with EoE.
2. Case summaries
2.1. Case 1
A 15-year-old female with CF (genotype: F508del/N1303K),
mild lung disease (baseline FEV1 of 92% predicted), pancreatic
insufficiency, and optimal nutritional status experienced persistent
abdominal pain, nausea, and periprandial emesis despite ongoing
proton pump inhibitor use. At an outside facility, abdominal
ultrasound revealed cholelithiasis and a laparoscopic cholecystec-
tomy was performed. Symptoms did not improve and the patient
consequently experienced a 2 kg weight loss. Gastric emptying
study, magnetic resonance cholangiopancreatography (MRCP),
and a brain MRI were normal. Esophagogastroduodenoscopy
(EGD), performed while the patient was taking esomeprazole20 mg twice daily, was normal; however esophageal biopsies
revealed 35 eos/hpf. In the absence of competing causes of
esophageal eosinophilia, this finding was consistent with a
diagnosis of EoE. RAST testing for common pediatric allergens
was negative. After three weeks of treatment with a swallowed
budesonide slurry (1 mg/2 ml) twice daily, her symptoms
completely resolved. Budesonide therapy was continued for a
total of 16 weeks, during which time the medication was slowly
tapered off. She remained symptom free off therapy for
approximately18 months, after which she had recurrence of
abdominal pain and nausea. Her parents opted not to subject her
to the additional risk involved with a second endoscopy, and her
symptoms improved with an additional 4 weeks of budesonide
therapy and remained in remission over the following 4 months of
follow-up.
2.2. Case 2
A 4-year-old female with CF (genotype: F508del/F508del),
pancreatic insufficiency, poor nutritional status, and presumed
GERD presented at 29 months of age with decreased oral intake.
Despite treatment with omeprazole 20 mg twice daily, she
subsequently developed severe food aversion and refusal to
swallow. These symptoms led to gastrostomy tube placement to
ensure adequate nutrition. Upper endoscopy revealed esophageal
congestion, linear furrows, punctuate white spots, and decreased
vascularity suggestive of EoE. Esophageal biopsies confirmed
this impression with increased eosinophils (N50 eos/hpf with
eosinophil microabscesses). Further testing revealed allergies to
soy, cantaloupe, peas, trees and grasses. Given the severity of her
symptoms, she was started on an elemental diet by gastrostomy
tube as well as a swallowed budesonide slurry of 0.5 mg twice
daily. After six months of therapy with improvement in her
symptoms and weight, she underwent repeat endoscopy. While
the esophagus had a markedly improved appearance, biopsies
revealed persistent eosinophilia (30 eos/hpf). The budesonide
dose was increased to 1 mg twice daily and follow-up endoscopic
examination revealed a normal esophageal mucosal appearance
and normal biopsies. After her initial clinical improvement, she
had recurrent symptoms when the oral budesonide therapy was
stopped. She subsequently required maintenance on an elemental
formula administered via gastrostomy tube for symptom control.
2.3. Case 3
A 12-year-old male with CF (genotype: F508del/F508del),
normal lung function values (FEV1 113% predicted), pancreatic
insufficiency, and nutritional failure requiring gastrostomy tube
placement presented with chronic recurrent abdominal pain and
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inhibitor (PPI) trial of esomeprazole 40 mg twice daily. The
patient underwent EGD which showed diffuse granularity of
the esophageal mucosa as well as linear furrows and decreased
vascularity throughout the esophagus. Biopsies showed
40 eos/hpf, consistent with EoE. Skin prick testing was
positive for peanut, egg, soy, wheat, and corn allergies. He
was started on a swallowed budesonide slurry and a targeted
elimination diet with improvement in his symptoms. Repeat
EGD at the end of three months of budesonide therapy showed
complete resolution of pathologic findings. The slurry was
discontinued but the patient continued with the elimination
diet and symptoms of EoE remain under control.
3. Discussion
In this case series, we present three patients with known CF
and concomitant non-specific GI symptoms. After extensive
evaluations including treatment with high dose PPI therapy, all
three patients were diagnosed with EoE after meeting the
criteria of the current consensus guidelines [2]. The variable
endoscopy findings and clinical outcome in each of these cases
is important to emphasize. In each scenario, despite compatible
symptoms, the diagnosis of EoE was not clinically suspected
prior to obtaining the endoscopy and biopsy results. We believe
this is related to a dearth of information in the literature about
the possible co-existence of EoE and CF, as well as the fact that
EoE has only recently emerged as an important etiology of GI
symptoms. We present this case series and literature review to
educate CF specialists about the diagnostic possibility of EoE
in CF. To our knowledge, the cases presented herewithin
document the first published cases of EoE in patients with CF.
3.1. Epidemiology and differential diagnosis
While the true incidence and prevalence of EoE are not
known, one survey of GI and allergy providers estimates an
overall prevalence of 52 cases/100,000 persons in the United
States, similar to a recent report from Europe [4–6]. One
difficulty in accurately determining the epidemiology of EoE is
that there are a variety of diseases besides EoE which can result
in esophageal eosinophilia, making the diagnosis of EoE
challenging. These disorders include GERD, eosinophilic
gastroenteritis, hypereosinophilic syndrome, connective tissue
disorders, celiac disease, Crohn's disease, parasitic infections,
and drug hypersensitivity, among others [3].
It is therefore important to note that the finding of eosinophils
on an esophageal biopsy specimen in and of itself does not suffice
for a diagnosis of EoE. On a practical level, GERD is the most
common condition that needs to be differentiated from EoE [7].
The symptoms of GERD overlap with EoE (heartburn, regurgi-
tation, dysphagia). GERD is a common indication for upper
endoscopy and is a common cause of esophageal eosinophilia.
Therefore, a trial of proton pump therapy is indicated before
making a diagnosis of EoE, and this intervention is often done
prior to an invasive study such as EGD [3]. Related to the PPI trial
is a newly recognized and somewhat controversial subgroup ofpatients with a phenomenon termed proton pump inhibitor-
responsive esophageal eosinophilia (PPI-REE) [2,8]. In this
situation, a patient with suspected EoE who has biopsy proven
esophageal eosinophilia has a symptomatic and histologic
response to PPI treatment alone. While there is preliminary
evidence that PPIs may have an anti-inflammatory effect separate
from their typical anti-acid effect [9], it is unknown if this PPI-REE
subgroup is an EoE phenotype [10], a GERD phenotype, a
combination of the two, or a separate condition altogether [2,5].
3.2. Symptoms, endoscopic, and histologic findings
Many of the conditions in the differential diagnosis for
esophageal eosinophilia can be seen concomitantly with CF and
present with overlapping symptoms. Feeding difficulties and
failure to thrive are common in infants and young children with
EoE, while school age children tend to present with emesis and
abdominal pain. Adolescents and adults may complain of
dysphagia, chest or abdominal pain, heartburn, or food impaction
[3,7].While the natural history of EoE is unknown, it is intriguing
to speculate that the different presenting symptoms may be
related to disease progression over time [3,7]. When asking
patients about symptoms of dysphagia, it is important to note that
both children and adults with EoE rapidly adapt their eating
habits (slow eating, thorough chewing, food avoidance) to
minimize symptoms, so questions on history should also address
dietary modification [2]. Because the symptoms in EoE are
non-specific and are also common in CF, when a patient with CF
presents with food avoidance, emesis, regurgitation, heartburn, or
dysphagia, EoE should be considered, particularly if symptoms
do not respond to empiric treatment and if endoscopic evaluation
is contemplated.
On endoscopy, there are several typical findings of EoE,
including esophageal rings, esophageal strictures or a narrow-
caliber esophagus, linear furrows in the esophageal mucosa,
white plaques or exudates, and mucosal pallor, congestion, or
decreased vascularity. However, similar to symptoms of EoE,
no single endoscopic finding can be considered pathognomic
for EoE. Therefore, it is important to maintain a high index of
suspicion and obtain esophageal biopsies when the diagnosis of
EoE is clinically suspected. Increasing biopsy numbers yield
higher diagnostic sensitivities [11], and biopsies should be taken
even if there is no gross evidence of esophageal abnormalities as
up to 10% of endoscopies may be visually normal [12].
On histopathologic examination of the esophageal biopsy, a
dense eosinophilic infiltration, eosinophilic microabscesses,
eosinophil granules, fibrosis, and basal cell hyperplasia can be
seen [13]. Current diagnostic guidelines recommend that in
addition to the eosinophil count, other pertinent findings should
be reported because in isolation, none of the pathologic features
are pathognomic for EoE. Because there is no single finding
that differentiates EoE from other conditions, the diagnosis of
EoE can only be made by linking compatible clinical symptoms
with histopathologic findings and excluding other potential
causes of esophageal eosinophilia. Prior to the 2007 consensus
diagnostic guidelines for EoE [1,2], there was substantial
variability in diagnostic criteria, which makes some of the
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confusion as well [12]. In the future, more specific staining of
the esophageal biopsies might aid with diagnosis, as several
studies have suggested that eosinophil granule deposition and
staining for esophageal mast cells may help diagnose EoE more
efficiently [14–17]. In addition, eotaxin-3 has been found to be
over-expressed in patients with EoE but not GERD [18] and
this may also be helpful for diagnosis in the future.
With regards to diagnosing EoE in CF, there are several special
considerations. First, since an EGD, an invasive procedure
requiring sedation with its associated risk of aspiration, is required
for diagnosis, it makes sense to minimize the number of
procedures needed and combine the procedure with any other
sedated procedures that may be required. Secondly, many patients
with CF are routinely maintained on a PPI, either for symptomatic
GERD or to enhance pancreatic enzyme efficacy. When EoE is a
clinical consideration, if the patient is not already on a PPI, he or
she should be placed on a high-dose twice daily PPI for at least
8 weeks prior to the procedure. Since CF patients are known to
require high doses of PPI for adequate acid suppression, the
clinician might also consider obtaining ambulatory pH monitor-
ing to ensure appropriate neutralization of gastric and esophageal
acid. Finally, inadvertent swallowing of a small amount of an
inhaled corticosteroid used for asthma may mask the underlying
diagnosis of EoE. If it is considered safe, this medication should
be held prior to the endoscopy to avoid missing the diagnosis.
3.3. Allergic associations and pathogenesis
The underlying pathogenic mechanism of EoE is still being
clarified, but the current belief is that EoE is an immune-mediated
condition in which allergens prompt a Th2 response where IL-5
and IL-13 stimulate the esophageal epithelium to produce
eotaxin-3, a potent eosinophil chemokine. This chemokine
recruits eosinophils into the esophagus and may lead to decreased
barrier function [19]. The cytokine IL-5 deserves special mention
as it promotes the production of eosinophils from the bone
marrow. IL-5 has been identified in EoE biopsy specimens and is
known to induce eosinophil-mediated esophageal remodeling in
mouse models [2].
Clinically, atopic diseases are commonly associated with EoE,
including asthma, atopic dermatitis, allergic rhinitis, sinusitis, and
food allergies [20]. Radioallergosorbent testing for specific IgE
and skin prick testing are the most common diagnostic testing for
food allergens, but atopy patch testing (for delayed, Type IV,
non-IgE mediated reactions) can also be used [3]. Interestingly,
patch testing suggests that the range of food protein allergy in
EoE is much more extensive than typical IgE-mediated food
allergy [21], though this modality is not universally available. In
most patients with EoE, culprit food allergens can be identified
through a range of allergy testing, and an elimination or elemental
diet is effective in controlling symptoms. When offending food
allergens are reintroduced, symptoms and esophageal eosino-
philia recur, and unlike typical food allergies, patients with EoE
do not usually outgrow their allergic response to the offending
foods [22–24]. Seasonality has also been shown to be a factor in
the diagnosis of EoE, corresponding to the season with the mostaeroallergens for the patient [3,7], but on a practical level it is
difficult to eliminate all environmental allergens to determine if
they are etiologic.
The pathogenesis of CF does not appear to overlap with that
of EoE, and food allergies in CF have rarely been reported [25].
However, atopic diseases are widespread, and when atopy is
encountered in patients with CF and GI symptoms, EoE should
be a diagnostic consideration. Anecdotal evidence suggests that
food allergies may be quite common but are often overlooked
clinically and not reported in the literature. When EoE and CF
overlap, clinicians should search for food allergies. In our small
series, two of the three patients were found to have specific
food allergies.
3.4. Treatment options
There are several options for treatment of EoE, including
pharmacologic agents and dietary elimination. Consensus recom-
mendations advocate for first line treatment of either swallowed
(“topical”) corticosteroids or dietary therapy, depending on patient
preference, severity of illness, and availability of local expertise
[2]. Reflecting this, a survey of 1800 adult and pediatric
gastroenterologists and allergists indicated that 44% prescribed
swallowed corticosteroids and a PPI as first line therapy, with
another 39% selecting an elimination diet as first line therapy [4].
PPI therapy alone is not effective for EoE (though by definition it
is appropriate for PPI-REE, as discussed above).
While there are no FDA-approved medications for EoE, the
use of swallowed corticosteroid is a mainstay of EoE therapy.
In this approach, a steroid inhaler such as fluticasone is puffed
into the mouth and then swallowed, or aqueous budesonide
respules can be mixed into a syrup with sucralose or another
thickening agent and swallowed directly. Efficacy of both of
these agents has been confirmed in recent randomized placebo-
controlled clinical trials [26,27]. It is important to note that EoE
frequently recurs when steroid therapy is discontinued, and the
approach to long-term maintenance medical therapy is still
unclear [2]. Although well tolerated compared to systemic
steroids, swallowed corticosteroids do carry a small risk of
candidal esophagitis [28].
Dietary therapy can be very effective in children if culprit
food allergens are identified, and recent data show efficacy in
adults as well [22–24]. Strategies that have been shown to be
effective include eliminating the most common food allergens
from the diet (“six-food elimination diet” where wheat, soy,
milk, egg, nuts, and seafood are restricted), performing food
allergy testing and eliminating offending agents (“targeted
elimination diet”), or using an allergen-free diet consisting only
of an elemental formula (“elemental diet”). Although the most
restrictive and least appropriate for most patients in the long
term, studies have shown that amino acid based elemental diets
are the most effective in eliminating esophageal eosinophilia
[22]. In general, proven food triggers likely need to be restricted
permanently [2].
In the context of CF, EoE treatment presents some special
concerns.While medical treatment with topical steroids is usually
well tolerated, this does add another medication to an already
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swallowed/topical steroids can impact the adrenal axis and bone
health, which can already be affected in CF. Restrictive dietary
therapy in EoE may be at odds with nutritional approaches in CF
where patients are instructed to consume large amounts of
calories due to increased metabolic demands. Consultation with a
registered dietician is warranted to ensure adequate nutritional
intake, especially if multiple allergens are identified and need to
be eliminated from the diet.3.5. Prognosis and importance of EoE in CF
EoE is a chronic, immune mediated condition defined by
eosinophilic-predominant esophageal inflammation associated
with clinical symptoms of esophageal dysfunction [2]. The
natural history of EoE is incompletely described, but while EoE
is chronic and symptoms persist without treatment and generally
recur if treatment stops, it does not yet appear to progress to other
eosinophilic GI conditions or malignancy [3,29]. A number of
disease complications, including food impaction and esophageal
stricture are common, but esophageal rupture is noted only in a
minority of patients. [2,30]. In patients with CF, underlying EoE
may clinically result in persistent emesis, food aversion, and
failure to thrive. The association of CF lung disease and nutritional
failure is well documented, so timely diagnosis of a potentially
treatable condition such as EoE is imperative. The association of
EoE and CF is likely not mechanistically related, since EoE is a
Th-2 allergen-mediated process and CF is a genetically deter-
mined disease. However, when EoE is suspected in a patient with
CF, it is important for the clinician to relay concerns about
potential EoE to the endoscopist, as biopsies need to be taken to
evaluate for the disease regardless of the endoscopic appearance of
the esophagus. If the concern for EoE is not adequately conveyed
to the endoscopist, the diagnosis could easily be missed.
We believe these are the first reported cases of EoE diagnosed
in patients with CF and it is possible that EoE has been
underappreciated in CF because of symptom overlap with other
common GI disorders in CF, including GERD, cholelithiasis,
pancreatic insufficiency, and adverse drug reactions. EoE should
be considered as a potential diagnosis in children presenting with a
compatible clinical scenario, failure to respond to PPI therapy, and
after exclusion of other potential GI causes. Because symptoms of
EoE are non-specific, a high degree of suspicion is necessary to
diagnose this entity in the CF population.References
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